Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
Cyclacel Pharmaceuticals, Inc. (CYCC)
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cyclacel.com/investor-relations
Company Research
Source: Yahoo! Finance
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The US$2.4m market-cap company announced a latest loss of US$23m on 31 December 2023 for its most recent financial year result. The most pressing concern for investors is Cyclacel Pharmaceuticals' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. View our latest analysis for Cyclacel Pharmaceuticals According to the 2 industry analysts covering Cyclacel Pharmaceuticals, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$25m in 2026. So, the company is predicted to breakeven approximately 2 years from today. What rate will the company have to grow
Show less
Read more
Impact Snapshot
Event Time:
CYCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCC alerts
High impacting Cyclacel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CYCC
News
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules [Yahoo! Finance]Yahoo! Finance
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesGlobeNewswire
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
CYCC
Earnings
- 3/19/24 - Beat
CYCC
Sec Filings
- 5/2/24 - Form 8-K
- 4/29/24 - Form RW
- 4/29/24 - Form 10-K/A
- CYCC's page on the SEC website